Nexthera Capital’s Alexion Pharmaceuticals ALXN Stock Holding History

Nexthera Capital’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-72,400	Closed	-$8.66M	–	58
2017 Q4	$8.66M	Buy	+72,400	New	+$8.82M	1.6%	21

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Nexthera Capital's ALXN Position: Q3 2018 in Review

Nexthera Capital sold out of Alexion Pharmaceuticals (ALXN) in Q3 2018, closing a stake of 132,623 shares — an estimated $16.5M sold.

Nexthera Capital first reported a position in ALXN in Q4 2016 and held it in 5 quarters. The position peaked at $16.5M in Q2 2018. 585 funds tracked by Wall St. Rank hold ALXN as of Q3 2018.

Nexthera Capital reported no remaining Alexion Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Nexthera Capital sold 132,623 Alexion Pharmaceuticals shares in Q3 2018, an estimated $16.5M.
Nexthera Capital first reported a position in Alexion Pharmaceuticals in Q4 2016 and held it in 5 quarters.
Nexthera Capital's Alexion Pharmaceuticals position peaked at $16.5M in Q2 2018.
585 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2018.

Based on Nexthera Capital's 13F filing for Q3 2018, filed 14 Nov 2018.